Sugammadex: A novel agent for the reversal of neuromuscular blockade

Pharmacotherapy

Volumn 27, Issue 8, 2007, Pages 1181-1188

  Nicholson, Wayne T ^a   Sprung, Juraj ^a   Jankowski, Christopher J ^a  

^a Mayo Clinic   (United States)

Author keywords

Cholinesterase inhibitor; Cyclodextrin; Org 25969; Rocuronium; Sugammadex

Indexed keywords

ATRACURIUM; ATROPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CISATRACURIUM; DOXACURIUM; GAMMA CYCLODEXTRIN; GLYCOPYRRONIUM BROMIDE; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENT; PANCURONIUM; ROCURONIUM; SUGAMMADEX; SUXAMETHONIUM; VECURONIUM;

ABNORMAL URINE COMPOSITION; AGITATION; ANEMIA; AREA UNDER THE CURVE; BODY TEMPERATURE; BRADYCARDIA; BRONCHUS SECRETION; CLINICAL TRIAL; COUGHING; DEHYDRATION; DELIRIUM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG SELECTIVITY; DYSPNEA; FEVER; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERKALEMIA; HYPOTENSION; MALAISE; NAUSEA; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR FUNCTION; PAROSMIA; PERISTALSIS; POLYURIA; RESPIRATORY FAILURE; REVIEW; RHINITIS; SIDE EFFECT; SINGLE DRUG DOSE; SMELLING DISORDER; TACHYCARDIA; TASTE DISORDER; URINE RETENTION; VERTIGO; VOMITING; XEROSTOMIA;

ANDROSTANOLS; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; FEMALE; GAMMA-CYCLODEXTRINS; HUMANS; MALE; NEOSTIGMINE; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR JUNCTION; NEUROMUSCULAR NONDEPOLARIZING AGENTS; RESPIRATION, ARTIFICIAL;

EID: 34547477926     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.8.1181     Document Type: Review

References (46)

1. Lee C. Structure, conformation, and action of neuromuscular blocking drugs. Br J Anaesth 2001;87:755-69.
2. Baraka A. Suxamethonium-neostigmine interaction in patients with normal or atypical cholinesterase. Br J Anaesth 1977;49:479-84.
3. Roy JJ, Varin F. Physicochemical properties of neuromuscular blocking agents and their impact on the pharmacokinetic-pharmacodynamic relationship. Br J Anaesth 2004;93:241-8.
4. Bevan DR. Monitoring and reversal of neuromuscular block. AmJ Health-Syst Pharm 1999;56:S10-13.
5. Grove SJ, Kaur J, Muir AW, Pow E, Tarver GJ, Zhang MQ. Oxyaniliniums as acetylcholinesterase inhibitors for the reversal of neuromuscular block. Bioorg Med Chem Lett 2002;12:193-6.
6. Stein RD, Backman SB, Collier B, Polosa C. Bradycardia produced by pyridostigmine and physostigmine. Can J Anaesth 1997;44:1286-92. (Erratum in Can J Anaesth 1998;45:382.)
7. Backman SB, Stein RD, Ralley FE, Fox GS. Neostigmine-induced bradycardia following recent vs remote cardiac transplantation in the same patient. Can J Anaesth 1996;43:394-8.
8. Lauven PM, Calaminus JM. Antagonisten in der Anasthesie. Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie 1995;30:331-6.
9. Nelskyla K, Yli-Hankala A, Soikkeli A, Korttila K. Neostigmine with glycopyrrolate does not increase the incidence or severity of postoperative nausea and vomiting in outpatients undergoing gynaecological laparoscopy. Br J Anaesth 1998;81:757-60.
10. Cheng CR, Sessler DI, Apfel CC. Does neostigmine administration produce a clinically important increase in postoperative nausea and vomiting? Anesth Analg 2005;101:1349-55.
11. Tramer MR, Fuchs-Buder T. Omitting antagonism of neuromuscular block: effect on postoperative nausea and vomiting and risk of residual paralysis. A systematic review. Br J Anaesth 1999;82:379-86.
12. Hovorka J, Korttila K, Nelskyla K, et al. Reversal of neuromuscular blockade with neostigmine has no effect on the incidence or severity of postoperative nausea and vomiting. Anesth Analg 1997;85:1359-61.
13. Boeke AJ. Does neostigmine cause nausea and vomiting? [comment] Anesth Analg 1995;80:849.
14. Ding Y, Fredman B, White PF. Use of mivacurium during laparoscopic surgery: effect of reversal drugs on postoperative recovery. Anesth Analg 1994;78:450-4.
15. Lovstad RZ, Thagaard KS, Berner NS, Raeder JC. Neostigmine 50 microg kg(-1) with glycopyrrolate increases postoperative nausea in women after laparoscopic gynaecological surgery. Acta Anaesthesiol Scand 2001;45:495-500.
16. Mirakhur RK. Antagonism of neuromuscular block in the elderly: a comparison of atropine and glycopyrronium in a mixture with neostigmine. Anaesthesia 1985;40:254-8.
17. Cooper MJ, Abinader EG. Atropine-induced ventricular fibrillation: case report and review of the literature. Am Heart J 1979;97:225-8.
18. Wolff MS, Weinberg I. The effect of ammonium glycopyrrolate (Robinul)-induced xerostomia on oral mucosal wetness and flow of gingival crevicular fluid in humans. Arch Oral Biol 1999;44:97-102.
19. Bellani AE, Rodola F, Cannelli G, Barbi S. Intravenous premedication with atropine and postanesthetic delirium: report of two cases. Rivista Europea Per Le Scienze Mediche e Farmacologiche 1991;13:137-9.
20. Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005;103:695-703.
21. Kopman AF, Chin WA, Moe J. Dose-response relationship of rocuronium: a comparison of electromyographic vs. acceleromyographic-derived values. Acta Anaesthesiol Scand 2005;49:323-7.
22. Eriksson LI. Evidence-based practice and neuromuscular monitoring: it's time for routine quantitative assessment. Anesthesiology 2003;98:1037-9.
23. Fuchs-Buder F, Mencke F. Use of reversal agents in day care procedures (with special reference to postoperative nausea and vomiting). Eur J Anaesthesiol 2001;23(suppl):53-9.
24. Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology 2003;98:1042-8.
25. Katz RL. Clinical neuromuscular pharmacology of pancuronium. Anesthesiology 1971;34:550-6.
26. Baurain MJ, Dernovoi BS, D'Hollander AA, Hennart DA, Cantraine FR. Conditions to optimise the reversal action of neostigmine upon a vecuronium-induced neuromuscular block. Acta Anaesthesiol Scand 1996;40:574-8.
27. Bartkowski RR. Incomplete reversal of pancuronium neuromuscular blockade by neostigmine, pyridostigmine, and edrophonium. Anesth Analg 1987;66:594-8.
28. Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007;329:1-11.
29. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 1996;85:1017-25.
30. Brewster ME, Loftsson T. The use of chemically modified cyclodextrins in the development of formulations for chemical delivery systems. Pharmazie 2002;57:94-101.
31. Loftsson T, Masson M. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm 2001;225:15-30.
32. Forgo P, Vincze I, Kover KE. Inclusion complexes of ketosteroids with beta-cyclodextrin. Steroids 2003;68:321-7.
33. Loftsson T, Stefansson E. Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye. Acta Ophthalmol Scand 2002;80:144-50.
34. Flood KG, Reynolds ER, Snow NH. Characterization of inclusion complexes of betamethasone-related steroids with cyclodextrins using high-performance liquid chromatography. J Chromatog A 2000;903:49-65.
35. Bar A. Cyclodextrins: preface. Regul Toxicol Pharmacol 2004;39(suppl 1):S1-2.
36. Adam JM, Bennett DJ, Bom A, et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem 2002;45:1806-16.
37. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angewandte Chemie, international ed 2002;41:266-70.
38. Hunter JM, Flockton EA. The doughnut and the hole: a new pharmacological concept for anaesthetists. Br J Anaesth 2006;97:123-6.
39. Kopman AF. Sugammadex: a revolutionary approach to neuromuscular antagonism. Anesthesiology 2006;104:631-3.
40. Tarver GJ, Grove SJ, Buchanan K, et al. 2-O-substituted cyclodextrins as reversal agents for the neuromuscular blocker rocuronium bromide. Bioorg Med Chem 2002;10:1819-27.
41. de Boer HD, van Egmond J, van de Pol F, Bom A, Booij LH. Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized rhesus monkey. Br J Anaesth 2006;96:473-9.
42. Epemolu O, Mayer I, Hope F, Scullion P, Desmond P. Liquid chromatography/mass spectrometric bioanalysis of a modified γ-cyclodextrin (Org 25969) and rocuronium bromide (Org 9426) in guinea pig plasma and urine: its application to determine the plasma pharmacokinetics of Org 25969. Rapid Commun Mass Spectrom 2002;16:1946-52.
43. Bom A, van Egmond J, Hope F, van de Pol F. Rapid reversal of rocuronium-induced neuromuscular block by Org 25969 is independent of renal perfusion [abstract]. Anesthesiology 2003;99:A1158.
44. Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003;99:632-7.
45. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 2006;104:667-74.
46. Shields M, Giovannelli M, Mirakhur RK, Moppett I, Adams J, Hermens Y. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006;96:36-43.